World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 85 14373 13533 7266 6724 538 43089

Natasha Rekhtman publications per year

The chart shows the history of publications by Natasha Rekhtman between 1997 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Natasha Rekhtman published across 29 years, from 1997 to 2025, averaging 21 papers a year. Output peaked at 255 publications in 2023. 62 of the 610 publications appeared in the last two years.

No. of publications
50 100 150 200 250
Bar chart. Horizontal axis: year, 1997 to 2025. Vertical axis: number of publications, 0 to 255. Peak 255 publications in 2023. 1997: 1 publication 1998: 0 publications 1999: 1 publication 2000: 0 publications 2001: 0 publications 2002: 0 publications 2003: 2 publications 2004: 0 publications 2005: 2 publications 2006: 0 publications 2007: 2 publications 2008: 6 publications 2009: 0 publications 2010: 7 publications 2011: 23 publications 2012: 10 publications 2013: 12 publications 2014: 12 publications 2015: 13 publications 2016: 16 publications 2017: 28 publications 2018: 25 publications 2019: 44 publications 2020: 30 publications 2021: 30 publications 2022: 29 publications 2023: 255 publications 2024: 31 publications 2025: 31 publications
1997 2025

610 publications in total across all disciplines

View publications per year as a table
Natasha Rekhtman: publications per year, 1997 to 2025
Year Publications
1997 1
1998 0
1999 1
2000 0
2001 0
2002 0
2003 2
2004 0
2005 2
2006 0
2007 2
2008 6
2009 0
2010 7
2011 23
2012 10
2013 12
2014 12
2015 13
2016 16
2017 28
2018 25
2019 44
2020 30
2021 30
2022 29
2023 255
2024 31
2025 31
Total 610
Download as CSV

Natasha Rekhtman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Natasha Rekhtman sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 521–540 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 538 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610 538
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Natasha Rekhtman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Natasha Rekhtman sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 84–85 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 85 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003 85
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Natasha Rekhtman is affiliated with Memorial Sloan Kettering Cancer Center in the United States and has a substantial body of work centered on pulmonary medicine and oncology. Their primary research contributions focus on lung cancer, encompassing aspects of diagnosis, treatment, genomics, and pathology.

The scientist has published extensively in several high-impact journals, with the most frequent publication venues including:

  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancer Research
  • Annals of Oncology

Research topics notably emphasized in their work comprise:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Neuroendocrine Tumor Research Advances
  • Lung Cancer Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Neuroblastoma Research and Treatments

Their research spans key fields of study such as Medicine and Biochemistry, Genetics and Molecular Biology. More specifically, they focus on subfields including Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research, and Epidemiology.

Natasha Rekhtman has contributed to several frequently cited papers, among them:

  • The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015 (2021) published in the Journal of Thoracic Oncology
  • A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee (2020) published in the Journal of Thoracic Oncology
  • Regenerative lineages and immune-mediated pruning in lung cancer metastasis (2020) published in Nature Medicine
  • SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization (2020) published in the Journal of Thoracic Oncology
  • Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer (2021) published in Cancer Cell

Collaborations are an important aspect of their work, with frequent co-authors including:

  • Charles M. Rudin
  • William D. Travis
  • Jason C. Chang
  • Marc Ladanyi
  • Marina K. Baine

Best Publications

  • Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

    Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg

  • Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network

    Eric A. Collisson;Joshua D. Campbell;Angela N. Brooks;Angela N. Brooks;Alice H. Berger

  • Comprehensive genomic characterization of squamous cell lung cancers

    Peter S. Hammerman;Doug Voet;Michael S. Lawrence;Douglas Voet

  • Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

    Helena A. Yu;Maria E. Arcila;Natasha Rekhtman;Camelia S. Sima

  • Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

    Patrick M. Forde;Jamie E. Chaft;Kellie N. Smith;Valsamo Anagnostou

  • Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

    Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila

  • Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

    Matthew D. Hellmann;Tavi Nathanson;Hira Rizvi;Benjamin C. Creelan

  • Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

    Jarushka Naidoo;Xuan Wang;Xuan Wang;Xuan Wang;Kaitlin M. Woo;Kaitlin M. Woo;Tunc Iyriboz;Tunc Iyriboz

  • The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015.

    Andrew G. Nicholson;Ming S. Tsao;Mary Beth Beasley;Alain C. Borczuk

  • In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system

    Danilo Maddalo;Eusebio Manchado;Carla P. Concepcion;Ciro Bonetti

  • Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

    Paul K. Paik;Paul K. Paik;Alexander Drilon;Alexander Drilon;Pang Dian Fan;Helena Yu;Helena Yu

  • Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

    Emmet J. Jordan;Hyunjae R. Kim;Maria E. Arcila;David Barron

  • Neuroendocrine tumors of the lung: an update.

    Natasha Rekhtman

  • EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

    Maria E. Arcila;Khedoudja Nafa;Jamie E. Chaft;Natasha Rekhtman

  • Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis

    Eric E. Gardner;Eric E. Gardner;Benjamin H. Lok;Valentina E. Schneeberger;Patrice Desmeules

  • p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma.

    Justin A Bishop;Julie Teruya-Feldstein;William H Westra;Giuseppe Pelosi

  • Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

    Alexander Drilon;Natasha Rekhtman;Maria Arcila;Lu Wang

  • Immunohistochemical Algorithm for Differentiation of Lung Adenocarcinoma and Squamous Cell Carcinoma Based on Large Series of Whole-Tissue Sections With Validation in Small Specimens

    Natasha Rekhtman;Daphne C Ang;Camelia S Sima;William D Travis

  • Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations

    Natasha Rekhtman;Paul K. Paik;Maria E. Arcila;Laura J. Tafe

  • Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets

    Natasha Rekhtman;Maria C. Pietanza;Matthew D. Hellmann;Jarushka Naidoo

Frequent Co-Authors

William D. Travis
William D. Travis Memorial Sloan Kettering Cancer Center
Charles M. Rudin
Charles M. Rudin Memorial Sloan Kettering Cancer Center
Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center
Marc Ladanyi
Marc Ladanyi Memorial Sloan Kettering Cancer Center
Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Maria E. Arcila
Maria E. Arcila Memorial Sloan Kettering Cancer Center
Alexander Drilon
Alexander Drilon Memorial Sloan Kettering Cancer Center
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
David R. Jones
David R. Jones Memorial Sloan Kettering Cancer Center
John T. Poirier
John T. Poirier New York University Langone Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The pathway to a medical career in the USA is diverse, with many related online degrees and certifications offering flexibility and affordability. For students aiming for advanced practice roles, the cheapest online dnp programs provide a more accessible option to earn a Doctor of Nursing Practice without heavy financial burden.

If you're interested in pharmacy, consider the 3-year online pharmd route. This accelerated option can help you become a pharmacist sooner, while balancing work and study.

For those looking to combine healthcare and technology, accredited healthcare informatics degree programs are increasingly popular. These programs prepare graduates to manage patient data and lead innovation in healthcare delivery.

Entry-level positions such as medical billing and coding can also be accessed quickly with a medical coding certification online. This certification opens the door to important administrative roles in clinics and hospitals, often without the need for years in a traditional classroom setting.

Exploring these related online degrees can help you find the right career path in the healthcare field, fitting your interests and lifestyle.

Best Scientists Citing Natasha Rekhtman

Trending Scientists

Recently Published Articles